Repligen (RGEN)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$165.05-2.06%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Increase adjusted EPS to $1.97-$2.05 in FY26: FY26 EPS guidance $2.03-$2.09 vs target $1.97-$2.05.
Repligen grows revenue about 9%-13% in 2026. Profit margin targets near 15.3% support earnings. Adjusted EPS aims for $1.97-$2.05 in 2026. The company shows solid progress on growth and margin goals.
Growth faces headwinds with recent revenue and EPS guidance cuts. The stock trades expensive with a PE near 78. Margin and EPS targets may be missed. Market enthusiasm for life sciences tools is softening.
The price is about 36% above our fair value near $103 and 33% below the Street median near $152. Analysts expect roughly 15% revenue growth. Our view is more cautious on valuation and growth sustainability.
Breaks if: Adjusted EPS falls below $1.97 in FY26
Breaks if: Operating margin falls below 15.1% in FY26
Breaks if: YoY revenue growth falls below 9% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on organic revenue growth. The current thesis state is intact, supported by recent earnings beats and management's confidence in growth targets.
The market appears to be pricing in an expensive valuation relative to peers, with an expectations gap indicating that investors anticipate strong performance. However, the valuation is considered unjustified given the current financial fragility.
Management is on track to achieve its organic revenue growth target of 10.5%-13.5% for FY26, but the adjusted EPS target shows mixed results. Recent financial performance has been strong, but there is a low probability of missing expectations, which could impact credibility.
The long-term thesis hinges on maintaining revenue growth and operating margins, as well as the performance of sector bellwethers. Additionally, any reversal in guidance or continued weakness in economic indicators could negatively impact RGEN's outlook.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'moderate'.
Yes, our read has strengthened. The company expects 9%-13% organic revenue growth in FY26. It also plans to expand its cell therapy market presence through the BioLife acquisition. There are no new threats affecting the read.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, RGEN's fundamentals are strong, but the elevated valuation and potential risks warrant caution. Not investment advice.